Zobrazeno 1 - 10
of 35
pro vyhledávání: '"Jill Reckless"'
Autor:
Richard M. Salmon, Jingxu Guo, Jennifer H. Wood, Zhen Tong, John S. Beech, Aleksandra Lawera, Minmin Yu, David J. Grainger, Jill Reckless, Nicholas W. Morrell, Wei Li
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-16 (2020)
The molecular basis of activin receptor-like kinase 1 (ALK1)-mediated endothelial bone morphogenetic protein (BMP) signalling is not fully understood. Here, the authors present crystal structures of the BMP10:ALK1 and prodomain-bound BMP9:ALK1 comple
Externí odkaz:
https://doaj.org/article/c95928c8f6c04cf69fb1889c1608aeab
Autor:
Daniel W Wheeler, Andrew J Thompson, Federico Corletto, Jill Reckless, Justin C T Loke, Nicolas Lapaque, Andrew J Grant, Pietro Mastroeni, David J Grainger, Claire L Padgett, John A O'Brien, Nigel G A Miller, John Trowsdale, Sarah C R Lummis, David K Menon, John S Beech
Publikováno v:
PLoS ONE, Vol 6, Iss 2, p e17152 (2011)
GABA(A) receptors are members of the Cys-loop family of neurotransmitter receptors, proteins which are responsible for fast synaptic transmission, and are the site of action of wide range of drugs. Recent work has shown that Cys-loop receptors are pr
Externí odkaz:
https://doaj.org/article/23173b15fc8b4b9690a691153a3c3a03
Autor:
Sophie Weil, Daniel Domínguez Azorín, Erik Jung, Josie Higgins, Hafeez Mohammed, Jill Reckless, Nigel Ramsden, Peter Keller, David Grainger, Wolfgang Wick, Frank Winkler
Publikováno v:
Neuro-Oncology. 24:vii210-vii210
Glioblastomas are known to be highly therapy resistant tumors. The description of tumor microtubes (TMs) as long cellular protrusions that connect glioblastoma cells to a network resistant against all standard therapies advanced the basic biological
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::551a6de0e254b6c11b47dbd9123c893f
https://doi.org/10.1093/neuonc/noac209.806
https://doi.org/10.1093/neuonc/noac209.806
Autor:
Keith P. Ray, Gareth Parkes, Suhail Nurbhai, Michael R. West, Luana Maggiore, Hafeez Mohammed, Timothy M. Carlton, J. Scott Crowe, Jill Reckless, Thomas T. MacDonald, Kevin J. Roberts, Marion F. Cubitt, Anna Vossenkämper, Peter M. Irving
Publikováno v:
Scientific Reports, Vol 9, Iss 1, Pp 1-12 (2019)
Scientific Reports
Scientific Reports
V565 is an engineered TNFα-neutralising single domain antibody formulated into enteric coated mini-tablets to enable release in the intestine after oral administration as a possible oral treatment for inflammatory bowel disease (IBD). Following oral
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::43bbbf0b55ab1ec44357c69676ca8cfd
http://link.springer.com/article/10.1038/s41598-019-50545-x
http://link.springer.com/article/10.1038/s41598-019-50545-x
Publikováno v:
Blood. 138:3181-3181
Background: FVIII deficient knock-out (F8 -/-) rats mimic the bleeding incidents seen in severe human hemophilia A (HA). Subcutaneous (SQ) marzeptacog alfa activated (MarzAA), a novel, engineered recombinant activated coagulation Factor VII (rFVIIa)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4bde821c40f938b1b43297e0af6192ce
https://doi.org/10.1182/blood-2021-151284
https://doi.org/10.1182/blood-2021-151284
Autor:
Marion F. Cubitt, Michael R. West, Simon Clare, Luana Maggiore, Thomas T. MacDonald, Keith P. Ray, Timothy M. Carlton, Kevin J. Roberts, Katherine Harcourt, J. Scott Crowe, Anna Vossenkämper, Jill Reckless
Publikováno v:
Scientific Reports
Scientific Reports, Vol 8, Iss 1, Pp 1-13 (2018)
Scientific Reports, Vol 8, Iss 1, Pp 1-13 (2018)
TNFα is an important cytokine in inflammatory bowel disease. V565 is a novel anti-TNFα domain antibody developed for oral administration in IBD patients, derived from a llama domain antibody and engineered to enhance intestinal protease resistance.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::258ab1e9c4b41aa5de1276195f915b1f
https://pubmed.ncbi.nlm.nih.gov/29563546
https://pubmed.ncbi.nlm.nih.gov/29563546
Publikováno v:
Blood. 134:2420-2420
Background: Patients with Hemophilia A or B with and without inhibitors lack treatment options that are fast and easy to use for treating acute bleeding. Currently, their only options are intravenous administration of replacement or bypass therapies.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::95dafbf8d213e12de514945d05b53b6b
https://doi.org/10.1182/blood-2019-128971
https://doi.org/10.1182/blood-2019-128971
A series of 3-acylaminocaprolactams are inhibitors of chemokine-induced chemotaxis. Branching of the side chain alpha-carbon provides highly potent inhibitors of a range of CC and CXC chemokines. The most potent compound has an ED(50) of 40 pM. Selec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5f3b22c06f765c80cc93f57a539daa4
https://ora.ox.ac.uk/objects/uuid:817ddac0-7e75-4b21-aaae-64d29e2fe93d
https://ora.ox.ac.uk/objects/uuid:817ddac0-7e75-4b21-aaae-64d29e2fe93d
Publikováno v:
Allergy. 64:539-550
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::babace1f9360c72e3f5bdcf87ef97ecc
https://doi.org/10.1111/j.1398-9995.2009.02077.x
https://doi.org/10.1111/j.1398-9995.2009.02077.x
Autor:
David J. Grainger, Daniel W. Wheeler, Jack F. Price, Andrew J. Grant, Jill Reckless, David K. Menon, John S. Beech, Pietro Mastroeni
Publikováno v:
Journal of Neuroimmunology. 184:198-208
Chemokines help to establish cerebral inflammation after ischemia, which comprises a major component of secondary brain injury. The CXCR4 chemokine receptor system induces neural stem cell migration, and hence has been implicated in brain repair. We
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6861d1f6d9b19b927c3cb806d6969580
https://doi.org/10.1016/j.jneuroim.2006.12.015
https://doi.org/10.1016/j.jneuroim.2006.12.015